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Abstract
Osteoarthritis (OA) is one of the most prevalent conditions resulting to disability 
particularly in elderly population About 13% of women and 10% of men aged 60 years 
and older have symptomatic knee OA. The proportions of people affected with symp-
tomatic knee OA is likely to increase due to the aging of the population and the rate of 
obesity or overweight in the general population. There are multiple factors associated 
with this progressive disease such as obesity, female gender, and repetitive trauma. Pain 
is the most common symptom in knee OA, a leading cause of chronic disability, clinical 
diagnosis will be supported by certain radiological findings. There are numerous con-
servative therapies that help to relive symptoms depend on severity of Osteoarthritis, 
and knee replacement remains standard of care in advance disease. Fat Micrografting 
is evolving technique with promising result in selected patients with regenerative and 
reparative effect of adipocyte-derived stem cell toward damaged cartilage and bone, 
which supported by clinical evidence.
Keywords: autologous fat micrograft, knee osteoarthritis, intra-articular injection,  
cartilage degeneration, adipocyte stem cells
1. Introduction
Rheumatic and musculoskeletal diseases (RMDs) constitute a group of more 
than 150 Conditions that are commonly characterized by progressive lesions and 
painful symptomatology. Altogether, they account for the leading cause of morbid-
ity and disability worldwide, giving rise to tremendous health expenditures and 
professional incapacity. Osteoarthritis (OA), one of the RMDs, is a degenerative 
condition that principally involves the joint’s cartilage, leading to its progressive 
destruction. It is related to aging and lifelong continual stress on the most func-
tional articulations such as the knees, hips, and fingers, and the lower spine region. 
OA ranks among the ten most disabling conditions in developed countries. The 
global prevalence of symptomatic OA is estimated as 9.6% in males and 18.0% in 
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females over 60 years of age. Further, 80% of individuals with OA would experi-
ence significant movement limitations, and 25% would have serious handicap to 
perform routine activities of the daily life [1].
The prevalence of OA varies in different regions of the world, with rates ranging 
from 3.8–70%, depending on the methodology of studies, whether clinical, radio-
graphic, patient self- reporting, or physician diagnosis [2]. As the incidence and 
prevalence of OA increase with age, the extending life expectancy results in a grow-
ing number of people afflicted with OA, with a proportional risk of disability. In 
the United Kingdom, 20–30% of the elderly population (aged 60 years and above) 
are diagnosed with symptomatic OA [3]. In the Middle East countries, including 
Iraq, Yemen, Saudi Arabia, and Syria, more than one million people are estimated to 
have OA [4]. Approximately 85% of individuals over the age of 75 experience some 
symptoms of OA [5].
Knee pain represents more than 80% of the total burden of OA [6]. High body 
mass Index (BMI) has become an epidemic in the US in recent decades and is a well-
known risk factor for knee OA [7]. In Saudi Arabia, a clinically based epidemiologi-
cal study, at a primary healthcare clinic, by Al-Shammari et al. showed a prevalence 
of OA as high as 57.2%. Other data by Al Arfaj estimated the prevalence of knee OA 
as 53.3% and 60.9% in males and females respectively [8, 9].
The treatment of knee OA may use conservative measures including medica-
tions, Physiotherapy, and local injections, or surgical approach including total 
knee arthroplasty (TKA). TKA is highly effective in reducing articular pain and is 
associated with acceptable functional outcomes. The procedure of TKA is safe and 
is considered one of the most common and successful procedures in orthopedics.
2. Risk factors
Blagojevicy et al. did a systemic review and meta-analysis to study the risk 
factors of Knee OA in older patients. They included 85 out of 2233 studies screened. 
The main risk factors found were obesity, previous trauma, hand OA, female gender 
and older age [10].
High body mass index (BMI) is associated with development of knee OA, and it 
was proven that the physical disability of the patients affected by knee OA reduced 
after weight reduction [11].
Another meta analysis conducted by Muthuri et al. showed that knee injury’s his-
tory is one of the major risk factors associated with Knee OA and it should be included 
in any prevention program since it is preventable factor [12]. Genetic factor as shown 
in different studies is also associated with OA [13]. Increased loading or mal alignment 
of the joints is considered to be other factors that may lead to OA. So, in summary the 
risk factors can be classified into patient related factors like BMI, genetic, gender and 
age and joint related like previous injury, abnormal loading or malalignment [14].
3. Staging
In research, multiple variations of the Kellgren and Lawrence staging system 
have been used. However, the original one is: [15].
• grade 0 (none): definite absence of x-ray changes of osteoarthritis.
• grade 1 (doubtful): doubtful joint space narrowing and possible osteophytic 
lipping.
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• grade 2 (minimal): definite osteophytes and possible joint space narrowing.
• grade 3 (moderate): moderate multiple osteophytes, definite narrowing of 
joint space and some sclerosis and possible deformity of bone ends.
• grade 4 (severe): large osteophytes, marked narrowing of joint space, severe 
sclerosis and definite deformity of bone ends.
4. Management
General and clinical assessment of the patient will help in determining the 
appropriate. Treatment of osteoarthritis. The assessment of OA effect on patient’s 
function, daily activity, social relationship and quality of life should precede any 
treatment. The. Management plan has to be discussed with the patient thoroughly 
including the education of osteoarthritis, benefits and risks of various treatment 
options.
4.1 Non-surgical management
There are different non-surgical methods to treat joint OA. According to the 
Osteoarthritis Research society International (OARSI) guidelines published in 2019, 
patient education and land-based exercise with or without management of dietary 
weight are core treatments of knee related osteoarthritis. Non-steroid anti-inflam-
matory drugs (NSAIDs) are recommended in OA.
Management and its topical derivative are strongly recommended for patients 
with knee OA. COX-2 inhibitors or NSAIDs with proton pump inhibitor should be 
utilized in patients with gastrointestinal pathology. Oral NSAIDs are not recom-
mended for patients with cardiovascular diseases. Intraarticular injection with cor-
ticosteroids or hyaluronic acid is mainly used for knee OA. It is not recommended 
for poly articular or even hip OA. All these non-surgical methods are associated 
with different level of evidence in the literature [16].
4.2 Surgical management
Before surgical intervention is considered, the patient should have received the 
core conservative treatment. Arthroscopic debridement and lavage are not routinely 
recommended unless there is a clear justification such as mechanical block that can 
be resolved arthroscopically [17]. After failure of all non-surgical treatments and in 
advanced joint arthritis, the total joint arthroplasty using artificial joint is the best 
option. It should be done before the patient gets advanced functional limitations. It 
is very safe procedure and associated with sound outcome. Pre- and post-operative 
patient engagement in terms of having proper education and well-structured 
physiotherapy is crucial to end up with great results. The American Academy of 
Orthopedic Surgeons (AAOS) in their 2nd edition evidence-based guideline for 
the treatment of knee OA has published 15 recommendations. This includes self-
management exercise programs, weight reduction for painful knee and BMI < 25 
and NSAIDs (oral or topical) or tramadol for symptomatic patients. They could not 
recommend the use of glucosamine and chondroitin, Intra articular Hyaluronic 
acid injection and arthroscopic lavage and or debridement for patient diagnosed 
with knee OA. They were unable to recommend for or against the using of knee 
corticosteroid, growth factor, platelet rich plasma (PRP) intraarticular injec-
tions and arthroscopic partial meniscectomy for a torn meniscus in patients with 
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symptomatic OA. They also have stated that high tibial vulgus osteotomy might be 
performed for patients with painful medial knee joint OA [18].
5. Fat graft evolution
Neuber presented history of fat transplantation in literature initially in 1893 and 
he stated that smaller fat parcels tend to undergo less absorption [19], followed by 
communication from Czerny [20] Lexer [21], and Rehn [22]. In 1911, Bruning was 
the first to transfer autologous fat into the subcutaneous tissue for the purpose of 
soft-tissue augmentation [23]. 1950 Peer published 1st book about fat grafting in 
300 pages, mentioned that survival rate of fat graft could be 50% and determined 
the viability of fat tissue which injected [24], in 1980 s liposuction technique 
evolved which improved technically over time, 1985 Illouz [25] and Fournier [26] 
developed an comprehensive approach to fat transfer by syringe harvesting, called 
“microlipoinjection”. Fat harvest from liposuction became the simplest and easiest 
method to pursue fat grafting, which indicated to treat soft tissue depression and 
contour deformity. 1990 Coleman described steps of fat injection procedure and 
coins the term Lipostructure [27].
There is numerous indications for fat graft in esthetic and regenerative 
medicine, Fat grafting technique evolved over period of time and become 
standard of care use in esthetic and reconstructive cases, in era of regenera-
tive medicine, Lipoaspirate is consider source of fat micrograft which contains 
adipocyte derived stem cell (ADCS), growth factors, preadipocytes and cyto-
kines demonstrate promising clinical application in wide spectrum of pathology 
to regenerate and reform damaged biological structure and improve outcome as 
in Osteoarthritis which consider leading cause to disability particularly in elderly 
population [28].
6. The use of microfat graft for cartilage repair
Cartilage contain a small number of cells known as chondrocytes, which are 
responsible for maintaining a large extracellular matrix, 85% of cartilage consti-
tutes water and two categories of molecules: collagenous and noncollagenous [29], 
The main function of cartilage is to protect underlying bone from friction and act 
as gliding surface to enable motion, Articular cartilage is characterized as avascular, 
aneural, and alymphatic and, at maturity, of low metabolic activity [30], which 
entitle cartilage to special tissue with difficult task to repair it self, It has been 
demonstrated that early in the process of cartilage damage there is a rapid loss of 
glycosaminoglycans from the tissue [31], Thus, most large defects fail to heal, lead-
ing to a long-term prognosis of osteoarthritis [32].
7. Surgical technique to harvest fat
Fat is readily available and simple to harvest, with the fat grafting surgery itself 
shows a low donor-site morbidity, and is inexpensive and repeatable. Liposuction 
is considered one of the most frequently performed surgical procedures all over 
the world, Since its introduction in 1982 using a blunt cannula attached to a suc-
tion generating device, the procedure has been improved [33], Current technology 
for liposuction includes suction-assisted lipectomy, ultrasound-assisted, power-
assisted, laser-assisted, and radiofrequency-assisted liposuction [34].
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7.1 Harvesting of the adipose tissue
The first step in fat transfer to harvest fat by Many different liposuction tech-
niques, all with the aim of minimizing adipocyte damage and increasing its survival 
Chosen Donor site is pretreated with a tumescent solution which containing an 
anesthetic mixture of Lidocaine, Sodium bicarbonate to overcome the acidity of 
mixture and to reduce pain and discomfort at injection site,epinephrine to control 
bleeding by vasoconstrictive action and Normal saline, proportionally mixed 
according to surgeon preference, volume to be injected determine by the desire 
volume of fat harvest and accordingly 2–3 cc of tumescent mixture to each 1 cc of 
anticipated fat harvest.
There are a variety of suction methods from which one may choose. The stan-
dard techniques are the manual (Coleman technique) or suction-assisted liposuc-
tion (SAL). Negative pressure is applied With the Coleman technique and SAL in 
combination with gentle forward and backward movement of the cannula, causing 
physical disruption, thus allowing fat tissue harvest. These methods represent the 
current gold standard, and reports show a lack of stem cell damage and preserva-
tion of their regenerative potential [35].
There are multiple modifications of this method, including power-assisted 
liposuction (PAL), water jet- assisted liposuction (WAL), laser-assisted liposuc-
tion (LAL), ultrasound-assisted liposuction (UAL), and VASER (Vibration 
Amplification of Sound Energy at Resonance).
They all are developed to further facilitate the process of suctioning, with mini-
mal trauma to the donor site and maximal outcome in the requested esthetic result.
Large-bore cannulas decrease the mechanical sheer stress on the harvested cells, 
and subsequently increase the total number of viable aspirated cells, and Studies 
have showed an inverse relationship between cellular damage and the diameter of 
the instrument used to extract fat [36].
8. Processing of lipoaspirate
The goal of processing is to eliminate cellular debris, a cellular oil and excess 
of infiltrated solution [37]. These elements cause inflammation at the recipient 
site, which can be unfavorable for the fat graft. Also, blood must be removed as it 
accelerates the degradation of the transplanted fat.
Sedimentation: little traumatic and gives a large number of vital and intact 
adipocytes. However, this method contains smaller concentrations of stem cells 
and a substantial amount of cellular debris and thus making it harmful to graft 
survival [38].
Filtration techniques: more efficient in producing viable graft material for 
large-volume fat transfers. One example is Puregraft filtration system; which is a 
closed-membrane filtration system that was originally designed to prepare fat for 
isolation of the stromal vascular fraction. Another example of filtration is lipoaspi-
rate filtered with cotton gauze; this results in concentrating the fat and separating 
it from the infiltrated solution, oil and cellular debris. This method, as compared 
to centrifugation, showed no significant differences in the viability of transplanted 
fat cells.
Washing with normal saline: this preserves mesenchymal stem cells as well as a 
great number of adipocytes.
Centrifugation: considered the most frequently used technique. It separates 
fat from substances that increase the degradation such as blood, proteases, lipids, 
lipases, and it may concentrate the adipose stem cell fraction, potentially enhancing 
Rheumatoid Arthritis
6
graft survival, Coleman suggested a processing method where centrifugation speed 
is 3000 rpm for 3 min. This creates multiple layers; the upper level is composed 
primarily of oil, the middle portion is fatty tissue, and the lowest portion, which is 
the densest layer, is composed of fluids and blood. This method obtains the high-
est possible concentration of stem cells within aspirate. It has also the increased 
content of angiogenic growth factors such as fibroblast growth factor (FGF) and 
vascular endothelial growth factor (VEGF). To note that excessive centrifugal force 
may damage intact adipocytes and on the other hand better graft viability with low 
centrifugal forces.
9. Microfat graft preparation
Processing micro fat graft that require to process harvested fat graft through 
multiple micro pores filters that allow micro fat graft to pass through, these filters 
have different sizes that connected to Leur-leur 1–10 cc syringe.
10. Fat graft injection
Adipose tissue is injected in to the transplantation site through cannulas, where 
multiple tunnels are created on insertion, and fat is injected during withdrawal of 
the cannula. Graft through nutrition by tissue fluid absorption can survive up to 
48 h. Meanwhile, neovascularization is being established. Therefore, the diameter 
of the graft should not be more than 2 mm to avoid central necrosis. The osteoar-
thritic knee joint was injected with autologous intra-articular fat micrograft 15–20 
mL through the lateral approach according to the case in an amount that did not 
produce high pressure inside the joint and did not produce pain to the patients due 
to tension of the joint capsule [39].
11. Postoperative care
Postoperative care include antibiotics for one week, pain killers, and garment 
pressure dressing at injection and donor sites, encourage exercise and physiother-
apy, massage to reduce swelling.
12. Complications
Infection is the most devastating encounter complication which presented 
as redness, hotness, increase pain, and purulent collection, treatment depend 
on severity of infection ranging from I.V antibiotics in addition to incision and 
drainage.
13. Fat is source of adipocyte derived stem cells (ADSC)
Adipose tissue composed of mature adipocytes (>90%) and a stromal vascular 
fraction (SVF), which includes preadipocytes, fibroblasts, vascular smooth muscle 
cells, endothelial cells, resident monocytes/macrophages, lymphocytes, ADSC, 
cytokines and growth factors [40–46], led to a growing interest for the use fat 
graft as regenerative therapy for common bone and joint diseases, with promising 
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therapeutic clinical application of ADSC into skeletal system with underlying 
structure such as Muscle, cartilage, ligament, tendon, and bone with regenerative 
and reparative potential and ADCs are considered as an ideal source of cell therapy 
for different types of diseases including bone and joint diseases [47].
14. Adipocyte derived stem cell role in regenerate knee osteoarthritis
Adult stem cells, represented mainly by the mesenchymal stem cells (MSCs) 
are present in most organs and tissues of the human body; they intend to replace 
damaged cells as a normal process [48]. These stem cells do not have ethical or legal 
concerns as compared to the embryonic and fetal stem cells [49]. Mesenchymal 
stem cells are a promising tool for tissue regeneration. They are multipotent adult 
stem cells obtained from different sources like bone marrow (BM), adipose tissue, 
umbilical cord, placenta, synovial membrane [50]. These cells because they are 
located in fat and synovial membrane, they are most suitable for the treatment of 
osteoarthritis (OA) [51].
The International Society of Cellular Therapy (ISCT) defines mSCs by three 
characteristics [52]. They need to be plastic adherent, express specific markers like 
the CD105, CD90, and negative for CD34, CD45, HLA-DR [47, 53, 54]. MSCs can 
differentiate to mesodermal lineage cells (osteocytes, adipocytes, chondrocytes) 
[54]. These cells differentiate also into many other cell types, like myocytes, neu-
rons [55], cardiomyocytes and hepatocytes [56] in vitro and in vivo [57–59].
They are non-immunogenic cells as they lack the expression HLDR receptor, 
which makes them suitable for allogeneic transplantation [59]. These cells are 
capable of suppressing lymphocyte reactivity [60] and inhibit the production of 
inflammatory cytokines in vitro [61]. MSCs express cytokine and chemokine recep-
tors on their cell surface, which allows them to migrate to the site of injury [62]. 
The ability to suppress the immune response enabled their use in graft-versus-host 
disease and transplant rejection [63].
Each of the MSCs depending on their origins presents some differences. The 
BM-MSCs have high differentiation capability, but are difficult to get from bone 
marrow. The adipose MSCs are easily obtained from adipose tissue with high yield 
and strong suppressive capabilities [64]. The umbilical cord MSCs are easy to 
get after birth, they have high self-renewable and differentiation capacities. The 
synovial-MSCs have high proliferative and differentiation capacities and very low 
immunogenicity [64].
MSCs from BM from mouse and from human were the first to be identified 
and are the most studied [54, 58]. Adipose stem cells (ASCs) were first identi-
fied as stem cells in 2001, capable to differentiate into cartilage, bone and adipose 
cells [65].
The age of the donor reflects on the differentiation potential of the cells [66]. 
Umbilical cord MSCs (UC-MSCs) showed to be highly proliferative and with dif-
ferentiation potentials [67]. The drawbacks of the BM-MSCs are that the procedure 
to obtain the cells is painful, costly and does not yield high number of cells for cell 
therapy [49, 68, 69]. Besides, the procedure for BM isolation can result in potential 
infections [54].
Synovial-MSCs (S-MSCs) isolated and characterized first in 2001, are also prom-
ising tools for the treatment OA due to their natural homing in this site [70]. They 
were shown to have high chondrogenic differentiation capacities, high expression of 
type II collagen, compared to other sources of MSCs [71, 72]. S-MSCs are isolated in 
low numbers from different sites, like styloid fossa and paralabral synovium [73, 74]. 
They have low immunogenicity with high proliferation potentials [75, 76].
Rheumatoid Arthritis
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The adipose MSCs (A-MSCs) represent many advantages compared to other 
sources of the MSCs. They are abundant in the adipose tissue, adipose tissue is 
easier to get compared to BM, they have strong immunosuppressive capacities [47].
More research is needed to unveil the differences in the traits of A-MSCs isolated 
from different sites and their implications in therapy. Previously, it was shown that 
A-MSCs could differentiate from one site to another in term of their cell markers. 
The A-MSCs isolated from abdominal adipose tissue had high expression in CD31, 
CD45 and HLA-DR compared to the cells isolated from orbital adipose and had 
lower expression of CD73, CD90, CD105 and CD146 [77]. MSCs from adipose tis-
sue represent a good and a promising alternative to bone marrow MSCs. They share 
the same phenotype as MSCs from bone marrow apart from few. They differenti-
ate similarly to BM-MSCs into the three lineages, chondrocytes, adipocytes and 
osteocytes. Most importantly, they are easily obtained from liposuction aspirate of 
patients undertaking plastic surgery [65]. Adipose tissue contains greater number 
of stem cells than bone marrow (10 times higher) [59]. A large number of cells are 
required for transplantation. Stem cells isolated from adipose tissue or another 
source like bone marrow, need to be scaled up. At least 2x106 of MSCs is required 
per kilogram body weight [78].
MSCs from different sites (BM, adipose) tissue are heterogeneous cell popu-
lation [79]. Although MSCs from bone marrow and from adipose tissue have 
similar differentiation potential, there are minor differences. ASCs showed higher 
chondrogenic potential than MSCs from bone marrow [80]. Other study however, 
showed no significant differences between these two populations for chondrogenic 
differentiation in 2D culture but the BM-MSCs showed higher chondrogenic 
differentiation in 3D culture [81]. Proliferative capacities and osteogenic dif-
ferentiation of the MSCs from bone marrow are reduced with age [82]. According 
to previous report, MSCs can be affected differently depending on the disease. 
For example, it was reported that the BM- MSCs from osteoporotic patients had 
reduced osteogenic activity [82], whereas the BM-MSCs from OA patients did not 
show any differences with the normal patient [83]. In another, the chondrogenic 
and adipogenic differentiation of the MSCs were reduced in OA patients but not the 
osteogenic differentiation [84].
The expression of CD36 differed between donors from no expression to highly 
expressed [85]. However, all ASC extracted from different donors showed the 
expression of the CD90, CD73 and CD105. ASCs markers can change in expres-
sion depending on the age of cells in culture. CD106 is expressed in MSCs from 
bone marrow but not in ASCs where this latter expresses CD49b [52]. ASCs and 
BM-MSCs express CD29 (beta-1 integrin, important factor in angiogenesis) [74] 
and CD44 (hyaluronate receptor, important for neoextracellular matrix) and 
CD49e (alpha-5 integrin, important for cell adhesion to fibronectin) [59]. ASCs and 
BM-MSCs have been shown to secrete angiogenic growth factors, like VEGF, P1GF, 
bFGF, angiogenin, GM-CSF, MCP-1 and SDF-1alpha (Rehman, 2004; Kinnaird 
et al.; 2004), these could be involved in increased angiogenesis in ischaemic tis-
sue [59]. CD117 (stem cell factor) a marker for totipotency and pluripotency, 
was expressed in ASCs and BM-MSCs [85]. Based on the International Society 
for Cellular Therapy, the minimum criteria to define mesenchymal stem cells are 
CD105 and CD90, their potential to differentiate to adipocytes, chondrocytes 
and osteocytes and they are plastic adherent [86]. The expression of the CD34 is 
only reported on the adipose derived mesenchymal stem cells but the expression 
decreases in culture [87, 88] and the expression of CD105 increases [89] (Braun 
et al.; 2013). CD34 is expressed on ASCs before they are isolated from the stromal 
vascular fraction (SVF) [89] (Braun et al., 2013). The International Society for 
Cellular Therapy (ISCT) and the International Federation for Adipose Therapeutics 
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and Science (IFATS) agreed on these changes in phenotype of ASCs in SVF (uncul-
tured) or when cultured [90]. The SVF is referred to the cellular pellet containing 
ASCs and endothelial progenitor cells without adipocytes and immune cells, [89]. 
When the SVF is plated, the ASCs adhere to the surface and the rest of the cell 
population including non-adherent and non-proliferating cells, are removed [89]. 
ASCs could be isolated from SVF by culture or by magnetic-activated cell sorting 
(MACS) [89]. The advantage of the MACS isolation is cells can be prepared in few 
hours as required in clinical application. When cells need to be expanded, isolating 
the ASCs with culture is the best method. ASCs and SVF could be used for trans-
plant but the number of cells obtained from patients could limit the use of SVF. 
ASCs could be expanded to a large number of cells, which could be used for autolo-
gous transplant or banked for allogeneic transplant [89]. These differences could be 
due to site differences or due to the lack of standardized isolation method [91].
14.1 Clinical trials with ASCs
MSCs showed to have a big potential in clinical applications. The first clinical tri-
als run on the application of bone marrow MSCs in patients with Hurler syndrome 
and metachromatic leukodystrophy (MLD) after allogeneic hematopeitic stem cells 
transplant, showed no toxicity secondary to the bone marrow MSCs transplant and 
the recovery of some of the symptoms were suggested to be due to the transplanted 
MSCs [92]. Since then, hundreds of MSCs clinical trials were run on many condi-
tions including neurological diseases, cardiovascular, autoimmune and bone and 
cartilage diseases [93]. So far, there have been few approved clinical application for 
the MSCs in different countries. Few examples, are the application of allogeneic 
MSCs for the treatment of graft versus host disease (GVHD) in Japan, autologous 
bone marrow MSCs for amyotrophic lateral sclerosis and autologous adipose MSCs 
for Chron’s fistula, human umbilical cord blood-derived MSCs for osteoarthritis in 
South Korea, and in Europe the application of allogenic adipose MSCs for the treat-
ment of fistulas in Crohn’s disease [70].
There are few procedures for the treatment of cartilage injuries; the arthroplasty, 
microfat grafting and the autologous transplant of chondrocytes but a curative 
therapy still need to be developed [94, 95].
The autologous chondrocytes implantation is a surgical procedure that involves 
the isolation of autologous chondrocytes, expanding them in vitro then transplant-
ing them back to the patient [96]. The application of MSCs for knee repair showed 
to be more effective with fewer side effects from the surgical procedure of the 
isolation of chondrocytes [96]. There are many clinical trials on the applications of 
the MSCs for OA [70].
OA is a very common condition in adults, which affects articular cartilage, 
subchondral bone, synovial tissue and meniscus of the joint. This leads to cartilage 
degeneration, osteophytes formation, subchondral sclerosis and synovial hyperpla-
sia [97]. OA may be caused by joint injuries, obesity, aging and could be inherited 
condition [97].
Previous applications of MSCs for cartilage repair showed good outcomes. The 
BM-MSCs transplant in patients for defects in their knee cartilage and in athletes 
with the defect in femoral cartilage showed a good recovery of their functions [98].
MSC isolated from bone marrow, adipose tissue, umbilical cord, synovial 
membrane were previously used for the treatment of OA [64].
Since the discovery of ASCs, they have been used in many clinical trials for 
different diseases [90]. Success has been reported from different clinical trials using 
ASCs, but the mechanism of action is still not clear on whether cells would differen-
tiate into the tissue or modulate the immune system [89]. Direct application of the 
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human ASCs improved cardiac function when injected in animals with myocardial 
infarction [99]. This effect was believed to be due to trophic factors released by the 
stem cells and differentiation of the ASCs. Local administration of ASCs acceler-
ated the wound healing in normal and diabetic animals through differentiation into 
epithelial and endothelial lineage and neovascularization [100]. ASCs were applied 
to an injured skin due to radiotherapy, showed good healing process compared to 
the control [101]. ASCs although they have been used successfully in clinical trials, 
but their effects are not always achieved. There are many reasons that could impact 
the success of the use of ACS from one trial to another like cell separation, delivery 
methods, cell homing, engraftment and their survival [89]. Other factors might 
have an impact on the success of the use of ASCs like the type of liposuction proce-
dure, site of liposuction, age of the patient and the body mass index (BMI). These 
factors are being investigated. Extraction of fat with different techniques might 
have an impact on cell viability of stem cells, their proliferation and the phenotype 
due to the trauma generated during the procedure. It is important to examine the 
different liposuction techniques and their impact on the ASCs phenotype, prolifera-
tion, and stress level for downstream applications either in research or in clinical 
applications.
15. Conclusion
Knee osteoarthritis is most prevalence musculoskeletal disease which cause 
functional limitations and affect a person’s quality of life, there are known factors 
related to underling OA pathology such as Obesity, female gender and repetitive 
trauma to knee, Radiological finding such as subchondral cyst and narrowing of 
joint space, will support clinical diagnosis and staging of the disease using Kellgren 
and Lawrence staging system. Which will dictate the treatment modalities, in early 
stages conservative treatment such as modification of life style, rehabilitation, 
NSAID. Where advance stage surgical interventions ranging from arthroscopic 
debridement and lavage in case of blockage to total knee arthroplasty, which is 
being standard of care in severe condition.
Evolution of fat graft application in wide spectrum of clinical applications and 
have shown promising outcome to alleviate OA symptoms, where its contain adipo-
cyte stem cells which known with reparative and regenerative process with presence 
of signal cofactors such as platelets derived growth factors and other growth factors 
to repaired damaged cartilage, fat graft being harvested from donor site mostly from 
abdomen, then;lipoaspirate will undergo further processing to isolate pure fat out 
from oil and fluid layer, then fat graft filtered with connector to reach pure micro fat 
graft ready to inject into affected knee under sterile process with local anesthesia.
Numerous clinical trials conducted to examine efficacy of microfat graft and 
ASC injection into knee with OA which demonstrated improvement in the overall 
condition, and further research with larger samples being in the process of publica-
tion to support clinical application and examine safety of patients.
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